Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
Combining anastrozole with finasteride/dutasteride may affect hair, as anastrozole prevents testosterone from converting to estrogen, potentially increasing DHT. Users suggest using the lowest effective dose of anastrozole.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.
The user is considering switching from finasteride to RU-58841 for hair loss due to side effects and is concerned about its safety around cats. They are also seeking dosage suggestions and alternatives like pyrilutamide.
The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.
Topical 2-deoxy-D-ribose (2dDR) regrows hair in mice almost as well as 2% Minoxidil. However, 2dDR may contribute to oxidative stress and hair loss due to the formation of advanced glycation end products (AGEs).
User experienced severe allergic reactions and liver issues after a hair transplant, likely due to antibiotics and medications. Despite trying Minoxidil, the user faced further complications and is now seeking medical advice for potential future transplants.
The user is questioning why they are not experiencing hair loss like their family members. They are considering whether genetics or preventive treatments like Minoxidil, finasteride, or RU58841 might be influencing their hair retention.
A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.
RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.
The conversation is about a female's difficulty in obtaining a prescription for a DHT blocker other than Spironolactone for hair loss. She is seeking advice on the severity of her condition and discussing specific treatments like Minoxidil, Finasteride, and RU58841.
TurboMoe has been using 1mg finasteride and 2mL minoxidil daily for 6 months to reverse his frontal hair loss, with good results. He previously used finasteride in his 20's but stopped before having children due to low sperm count; he stayed off it until his last child was born.
A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
The user experienced heavy shedding 10 months after a hair transplant and used a topical solution of Minoxidil and Finasteride, later switching to Finoduta. They also dealt with a dry scalp and greasy hair, using various shampoos and conditioners, and sought advice on whether the shedding was normal and how to manage the dry scalp.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.
The user experienced genital itching while using finasteride and noticed a yellow bump, which improved with clotrimazole, but the itching persists. The discussion focuses on side effects of finasteride.
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.
Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.
Being overweight may increase finasteride side effects due to higher aromatase activity converting testosterone to estradiol. Maintaining a healthy weight could reduce these side effects.
Finasteride has been effective for maintaining hair density, but due to a slight dip in temple hair, the user switched to dutasteride as an additional measure. Users discuss varying experiences with side effects from finasteride, dutasteride, and minoxidil, highlighting that reactions can differ significantly among individuals.
Taking zinc and copper may offset copper depletion and potentially aid hair health when used with finasteride. The user is considering whether to use these supplements alongside finasteride or wait until switching to dutasteride.
Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.